scholarly journals Influence of VDR gene polymorphisms on the development and course of breast cancer

2021 ◽  
Vol 25 (4) ◽  
pp. 663-667
Author(s):  
D. S. Sukhan ◽  
H. P. Liudkevych ◽  
Y. O. Botanevych ◽  
Y. V. Lysytska ◽  
N. V. Haidukov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Extensive Literature ◽  
Vdr Gene ◽  
New Methods ◽  
Common Cancer ◽  
Number Of Patients ◽  
Vdr Gene Polymorphisms ◽  
New Treatments ◽  
The Cost ◽  
Development Course

Annotation. Breast cancer is the most common cancer diagnosed in women. In the last 5 years, it has been diagnosed in 7.8 million women, and in 2020, 685,000 deaths from breast cancer were registered. The growing number of patients with this pathology and the cost of therapy creates a need to study new methods of diagnosis and treatment. Therefore, detailed attention is paid to genetic risk factors for cancer, in particular, the VDR gene and its polymorphisms ApaI, TaqI, BsmI and FokI. Therefore, the purpose of this review is to collect and analyze currently known information about these SNPs and their relationship to the development, course and effectiveness of breast cancer treatment. To do this, an extensive literature review was conducted using basic databases, which described the effect of vitamin D3 on the tumor process and found that VDR receptor dysfunction increases the risk of breast cancer and affects the sensitivity of patients to treatment, which proves the effect of polymorphisms. ApaI, TaqI, BsmI and FokI on the development of pathology. Therefore, the prospects for further research are to study the prognostic value of each polymorphism and develop new treatments for the disease.

scholarly journals A Global Economic Model to Assess the Cost Effectiveness of New Treatments for Advanced Breast Cancer in Canada

2016 ◽  
Vol 19 (3) ◽  
pp. A151
Author(s):  
C Beauchemin ◽  
N Letarte ◽  
K Mathurin ◽  
L Yelle ◽  
J Lachaine
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Advanced Breast Cancer ◽  
Economic Model ◽  
Advanced Breast ◽  
New Treatments ◽  
The Cost

scholarly journals Trastuzumab As an Adjuvant Therapy for Early Breast Cancer: Economic Evaluation From a Malaysian Perspective

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 72s-72s
Author(s):  
F.K. Hanin ◽  
L. Sit Wai ◽  
J. Sabirin ◽  
W.P. Sharifa Ezat ◽  
D. Maznah
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Cost Effective ◽  
Effective Strategy ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Common Cancer ◽  
The Cost

Background: In Malaysia, breast cancer is the most common cancer in females and also the first most common cancer among population regardless of gender. The percentage of breast cancer detected at stage I and II was 61%, another 27% with locally advanced cancer and 11% with late stage metastatic cancer. From the total, 28% are human epidermal growth factor receptor 2 (HER2) positive and access to targeted therapy (trastuzumab) was very limited; only 19% of eligible patients could be treated. Aim: To determine the incremental cost-effectiveness ratio (ICER) between chemotherapy plus trastuzumab and chemotherapy alone as adjuvant treatment of early breast cancer from Malaysian perspective. Methods: A Markov cohort simulation was developed using Microsoft Excel Workbook 2007 to estimate the cost-utility of adjuvant trastuzumab compared with chemotherapy alone for treatment of early breast cancer with HER2 positive status. Two adjuvant treatment strategies were evaluated: 1) chemotherapy plus trastuzumab and 2) chemotherapy alone as adjuvant treatment. This Markov model was projected to lifetime horizon. All costs and outcomes were discounted at 3% and the cost-effectiveness result was expressed in ICER. One-way sensitivity analysis was performed to address the uncertainty. Results: The base case analysis indicated that 1-year adjuvant trastuzumab treatment generates a deterministic ICER of RM 83,544.59 per QALY gained. Over the lifetime, there is a marginal cost increase of RM 85,659.10 and a marginal benefit of 1.025 QALYs per patient when trastuzumab is added to standard chemotherapy compared with no trastuzumab strategy. Based on one-way sensitivity analysis, these components have shown to be a sensitive parameter for ICER determination: discount rate, disease-free state utility, route of trastuzumab administration and cost of trastuzumab. Conclusion: Addition of 1-year treatment with trastuzumab on top of standard adjuvant chemotherapy is considered as a cost-effective strategy for early breast cancer with HER2 positive, yielding an ICER of RM 83,544.59 per QALY gained, which is within the suggested value of cost-effectiveness threshold by WHO (1-3 times GDP per capita). However, if suggested threshold for Malaysia is taken into consideration, this treatment may not be a cost-effective strategy.

scholarly journals Do VDR Gene Polymorphisms Contribute to Breast Cancer?

2016 ◽  
Vol 17 (2) ◽  
pp. 479-483 ◽  
Author(s):  
Fouzia Shaikh ◽  
Saeeda Baig ◽  
Qamar Jamal
Keyword(s):  
Breast Cancer ◽  
Gene Polymorphisms ◽  
Vdr Gene ◽  
Vdr Gene Polymorphisms

scholarly journals Comparison of Grading and ER, PR Hormone Receptor Status of Carcinoma Breast in FNAC with Histopathology - A Cross Sectional Study from Thrissur, Kerala

2021 ◽  
Vol 8 (21) ◽  
pp. 1696-1700
Author(s):  
Suma Madathiveetil ◽  
Jisha Kalathil Thodiyil ◽  
Freena Rose
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Cross Sectional Study ◽  
Hormone Receptor Status ◽  
Sectional Study ◽  
Cross Sectional ◽  
Carcinoma Breast ◽  
Receptor Status ◽  
Common Cancer ◽  
Number Of Patients

BACKGROUND Breast cancer is now the most common cancer in cities in India and 2 nd most common cancer in the rural areas. Fine needle aspiration cytology (FNAC) is a less invasive pre-operative diagnostic method and is preferred over core / excision biopsy to decide the benign or malignant nature of the breast lump. Prognostic factor assessment by FNAC would allow the identification of patients who would benefit from neo adjuvant treatment (patients with grade 3 tumours) and in whom conservation surgery is inadvisable.1 The purpose of this study is to compare the grades of breast cancer in FNAC with histopathology as gold standard and compare the oestrogen (ER) and progesterone (PR) hormonal expression pattern on immunocytochemistry (ICC) with immunohistochemistry (IHC). From this study we intend to assess the usefulness of cytological grading and ER, PR hormone receptor status pre-operatively so that hormonal therapy can be included with neoadjuvant chemotherapy. METHODS This is a cross sectional study with a sample size of 50, conducted in the Department of Pathology. RESULTS Out of 50 cases, maximum number of patients were in the age group of 51 - 60 years. 68 % had attained menopause; 69 % of patients had tumour size between 2 - 5 cm and 90 % of tumours were in the upper outer quadrant of breast. Considering hormonal expression, in case of ER there was a moderate agreement between ICC and IHC (κ = .428, P = 0.005) and no agreement was seen in case of PR (κ = .073, P = 0.625). Regarding the cytological grading, this study showed highest degree of concordance with grade II tumours with a sensitivity of 75.9 %. For Grade I it was 2.5 % and for grade III, it was 33.3 %. CONCLUSIONS Evaluation of hormonal status and nuclear grading is fairly reliable on cytology when performed on qualitatively superior FNAC material from the primary breast lesions. KEYWORDS Carcinoma Breast, FNAC, ER / PR, Immunocytochemistry, Immunohistochemistry, Cytological Nuclear Grading

scholarly journals Vitamin D Receptor Gene Polymorphisms and Breast Cancer Risk in Kazakhstan

2014 ◽  
Vol 2 ◽  
Author(s):  
Ainur Akilzhanova ◽  
Zhannur Abilova ◽  
Nurgul Sikhayeva ◽  
Ivan Shtefanov ◽  
Abay Makishev ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Vitamin D Receptor ◽  
Gene Polymorphisms ◽  
Vdr Gene ◽  
Dihydroxyvitamin D3 ◽  
1,25 Dihydroxyvitamin D3 ◽  
Vdr Gene Polymorphisms

Introduction: The steroid hormone 1,25-dihydroxyvitamin D3 is thought to protect against breast cancer. The activity of 1,25-dihydroxyvitamin D3 is mediated via the vitamin D receptor (VDR), and a number of polymorphisms in the VDR gene have been identified. These result in distinct genotypes, some of which may alter susceptibility to breast cancer. Two common single nucleotide polymorphisms (SNP) in the VDR gene (VDR), rs1544410 (BsmI) and rs2228570 (FokI), have been inconsistently associated with breast cancer risk. Increased risk has been reported for the FokI ff genotype, which encodes a less transcriptionally active isoform of VDR. A reduced risk has been reported for the BsmI BB genotype which may influence VDR mRNA stability.Aim: We have investigated whether specific VDR gene polymorphisms are associated with breast cancer risk in Kazakhstan women.Material and Methods: In a case–control study, female breast cancer patients (315) and a female control group (n=604) were tested for two VDR polymorphisms. Statistical analysis was conducted using SPSS19.0.Results: The VDR rs2228570 (FokI) polymorphism was associated with an increased occurence of BC [rs2228570 (folk) ff vs. FF genotype: OR=1.71; 95% CI=1.21-2.43]. No association was noted between rs1544410 (BsmI) BB and breast cancer risk [OR=0.68; 95% CI=0.49-0.95].Conclusion: Although the factors that increase breast cancer susceptibility remain uncertain, future large studies should integrate genetic variation in VDR with biomarkers of vitamin D status. Additional testing on the effect of varying genotypes on the functional mechanisms of the VDR could help to improve future testing and treatment of woman at risk for breast cancer.

A generalized fuzzy cost efficiency model

2020 ◽  
Vol 54 (6) ◽  
pp. 1775-1791
Author(s):  
Nazila Aghayi ◽  
Samira Salehpour
Keyword(s):  
Cost Efficiency ◽  
Minimum Cost ◽  
Extensive Literature ◽  
Data Envelopment ◽  
Fuzzy Environment ◽  
Decision Making Unit ◽  
Production Possibility Set ◽  
Fuzzy Cost ◽  
The Cost ◽  
Generalized Cost

The concept of cost efficiency has become tremendously popular in data envelopment analysis (DEA) as it serves to assess a decision-making unit (DMU) in terms of producing minimum-cost outputs. A large variety of precise and imprecise models have been put forward to measure cost efficiency for the DMUs which have a role in constructing the production possibility set; yet, there’s not an extensive literature on the cost efficiency (CE) measurement for sample DMUs (SDMUs). In an effort to remedy the shortcomings of current models, herein is introduced a generalized cost efficiency model that is capable of operating in a fuzzy environment-involving different types of fuzzy numbers-while preserving the Farrell’s decomposition of cost efficiency. Moreover, to the best of our knowledge, the present paper is the first to measure cost efficiency by using vectors. Ultimately, a useful example is provided to confirm the applicability of the proposed methods.

Study of CDX-2 VDR gene polymorphisms in male infertility

2017 ◽  
Author(s):  
Suzana Vladoiu ◽  
Daniela Dinu Draganescu ◽  
Anca Botezatu ◽  
Dana Manda ◽  
Sabina Oros ◽  
...  
Keyword(s):  
Male Infertility ◽  
Gene Polymorphisms ◽  
Vdr Gene ◽  
Vdr Gene Polymorphisms
Sign in / Sign up

Export Citation Format

Share Document